EVOK - Evoke Pharma shares surge on positive findings from Gimoti market research study

Evoke Pharma shares jump ([[EVOK]] +14.4%) after it announces positive findings from a market research study for its diabetic gastroparesis treatment Gimoti.Evoke through its marketing partner, EVERSANA, conducted an ATU (Awareness, Trial, and Usage) study, a quantitative survey to measure physician awareness, trial, and product usage, for Gimoti.Healthcare practitioners indicated that the primary driver for prescribing Gimoti was a lack of effectiveness of current treatments.As part of a survey, which included about 104 total physician responses, a majority of each of the target and non-target gastroenterologists noted they intend to prescribe Gimoti for both new and existing gastroparesis patients.The FDA approvedGimoti (metoclopramide) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis, a disorder in which the stomach's contractions are disrupted, compromising digestion, in June last year.

For further details see:

Evoke Pharma shares surge on positive findings from Gimoti market research study